Immunotherapy Drugs Market Report with Competitive Analysis

Immunotherapy Drugs Market Report with Competitive Analysis

Immunotherapy Drugs Market Segmentation:

By therapeutic area, cancer accounted for the largest market share in 2019

On the basis of therapeutic area, this market is segmented into cancer, autoimmune & inflammatory diseases, infectious diseases, and other therapeutic areas. Cancer accounted for the largest share of the immunotherapy drugs market, by therapeutic area, in 2019. The large share of this segment can be attributed to the growing prevalence of cancer, rising research activity in this area, and reimbursement coverage for immunotherapies for oncology.

Cancer commanded the largest share of the immunotherapy drugs market, by therapeutic area, in 2019.

Based on therapeutic areas, the immunotherapy drugs market has been segmented into cancer, autoimmune and inflammatory diseases, infectious diseases, and other therapeutic areas. Cancer accounted for the largest share of the immunotherapy drugs market in 2019. Factors such as a large number of approvals, rising prevalence of cancer, rising demand for monoclonal antibodies & personalized medicines, and the expansion of policies by payers to cover most immunotherapy drugs are driving the market growth.

Download PDF:

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=137717755

Immunotherapy Drugs Market Overview:

The Immunotherapy Drugs Market is expected to grow at a CAGR of 11.0 percent over the forecast period, from USD 163.0 billion in 2020 to USD 274.6 billion in 2025. The rising prevalence of target diseases, increased demand for monoclonal antibodies and biosimilars increasing use of immunotherapy medications over traditional therapies, and a favorable approval scenario are all contributing to the market's growth. However, market growth is projected to be hampered by time constraints, side effects, manufacturing complexity, and a high attrition rate during the product development cycle.

Request For Free Sample:

https://www.marketsandmarkets.com/requestsampleNew.asp?id=137717755

Hospitals are the largest end-user segment of the immunotherapy drugs market.

On the basis of end-users, the immunotherapy drugs market is segmented into hospitals, clinics, and other end users. The hospital's segment accounted for the largest share of the immunotherapy drugs market, by end-user, in 2019. Factors contributing to the large share and high growth of this segment include the rising spending by hospitals on immunotherapies, the prevalence of cancer and autoimmune diseases, and the availability of the necessary infrastructure and facilities.

Get More Detailed Information

https://www.marketsandmarkets.com/Market-Reports/immunotherapy-drug-market-137717755.html

Key Market Players

The major players in the global immunotherapy drugs market are F. Hoffmann-La Roche Ltd. (UK), Pfizer Inc. (US), Merck & Co (US), Novartis International AG (UK), Johnson & Johnson (US), Sanofi (France), GlaxoSmithKline Plc (UK), Amgen Inc. (US), AbbVie Inc. (US), Boehringer Ingelheim (Germany), AstraZeneca (UK), and Immatics Biotechnologies (Germany), BioNTech SE, Genmab, Gilead Sciences, NBE Therapeutics, Teva Pharmaceuticals, Bayer, and Bristol-Myers Squibb.

About Us

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth emerging opportunities/threats which will impact 70% to 80% of worldwide companies revenues. Currently servicing 7500 customers worldwide including 80% of global fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their pain points around revenues decisions. Our 850 full-time analysts and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model - GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify the most important customers, write "Attack, avoid and defend" strategies, and identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high-growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve. MarketsandMarkets's™ flagship competitive intelligence and market research platform, "Knowledge store" connects over 200,000 markets and entire value chains for a deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:

Mr. Aashish Mehra

MarketsandMarkets™ INC.

630 Dundee Road

Suite 430

Northbrook, IL 60062

USA: 1-888-600-6441

sales@marketsandmarkets.com